| Filed On | Filing |
|---|---|
| 22 Jun 2015 |
8-K/A: Other Events
Updated Results from Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination with Ibrutinib Confirms Robust Clinical Activity with a Favorable Safety Profile in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leuke... |
| 05 May 2015 |
8-K/A: Results of Operations and Financial Condition
On May 4, 2015, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2015. TG also announced that on Tuesday, May 5, 2015 at 8:00am EDT, TG would host... |
| 23 Sep 2014 |
8-K/A: Entry into a Material Definitive Agreement
On September 22, 2014, TG Therapeutics, Inc. (the “Company”) exercised its option to license (“license option”) the global rights to TGR-1202, thereby entering into an exclusive licensing agreement (the “Agreement”) with Rhizen Pharmaceu... |
| 16 Mar 2012 |
8-K/A: Financial Statements and Exhibits
Consolidated Statement of Operations for the year and cumulative period ended December 31, 2011 |
| 03 Feb 2012 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Effective December 29, 2011, Douglas Abel, David C. Shimko and Richard Steinhart resigned from their positions on the Board of Directors of the Company. Michael McGuinness resigned both his seat as a director and as an officer of the Com... |
| 11 Mar 2011 | 8-K/A: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement |
| 24 May 2010 |
8-K/A: Completion of Acquisition or Disposition of Assets
We have audited the accompanying consolidated balance sheets of Ariston Pharmaceuticals, Inc. and subsidiary (A Development Stage Company) as of December 31, 2009 and 2008, and the related consolidated statements of operations, changes i... |
| 19 Sep 2005 |
8-K/A: Unregistered Sales of Equity Securities; Other Events
Manhattan Pharmaceuticals, Inc. (the "Company") recently sold in a private placement offering (the "Offering") to accredited investors units of its securities consisting of shares of common stock ("Shares") and warrants to purchase addit... |
| 15 Jun 2005 |
8-K/A: Completion of Acquisition or Disposition of Assets
This Agreement and Plan of Merger (this “Agreement”) is entered into as of April 1, 2005, by and among Manhattan Pharmaceuticals, Inc., a company duly organized and existing under the laws of the State of Delaware, having a place of busi... |
| 09 May 2003 |
8-K/A: Completion of Acquisition or Disposition of Assets
Our report on our audit of the financial statements of Manhattan Pharmaceuticals, Inc. (a development stage company) as of December 31, 2001 and the related statements of operations, changes in stockholders' deficiency and cash flows for... |
| 02 Jun 1999 |
8-K/A: Other Events
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ---------------------------------- |
Loading...